All In Biotech

Drug Trial Radar · NCT06742216

Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Monosialoganglioside in the Treatment of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,232 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,232

Actual

Start

Nov 3, 2020

Primary completion

Aug 30, 2023

Study completion Aug 30, 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke. It is estimated that 1706 patients will be enrolled and randomly assigned to the treatment group and the placebo control group in a 1:1 ratio. Normally, the duration of this study is approximately 90 days. Treatment was continued for 12\~14 days, and follow-up was conducted until the 90th day from the first dose. The trial is divided into three phases: screening/baseline phase, treatment phase, and follow-up phase. Screening/baseline period: After the subjects sign the informed consent form, they enter the screening/baseline period for screening examination. Treatment period: Qualified subjects are randomly divided into groups in a 1:1 ratio and receive continuous treatment for 12\~14 days (12\~14 times) with GM1 injection and placebo respectively. During the treatment period, relevant examinations and evaluations required by the protocol will be carried out. Follow-up period: Subjects who have completed treatment will enter the follow-up period until the 90th day of treatment.

Conditions

  • Acute Ischemic Stroke

Interventions

  • MonosialogangliosideDrug

    Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

  • PlaceboDrug

    Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of modified Rankin Scale (mRS) 0-2Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Gulou Medical College Affiliated Hospital

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.